Syncromune’s Phase 1 clinical trial of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) showed an 87% overall response rate, including a 53% complete response rate. The therapy was well-tolerated with mostly low-grade side effects. These findings will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
This news holds substantial promise for mCRPC patients, a group historically unresponsive to immunotherapy. The high response rates observed, particularly the complete responses with resolution of bone and soft tissue metastases, suggest a potential paradigm shift in the treatment landscape for this challenging disease. These data are especially encouraging given that current treatment options for mCRPC are often limited and associated with significant side effects. The positive safety profile observed in the Phase 1 trial further strengthens the potential of SYNC-T to become a valuable addition to the arsenal against prostate cancer.
The Phase 1 trial data demonstrate an impressive 87% overall response rate and a 53% complete response rate in mCRPC patients. Complete resolution of bone and soft tissue metastases was observed in all eight patients achieving a complete response. Further details on time to response, duration of response, progression-free survival, and overall survival will be presented at the ASCO meeting. Based on these promising results, SYNC-T Therapy SV-102 is now being evaluated in a U.S., multicenter, Phase 2a trial (LEGION-100) for mCRPC patients.
The positive Phase 1 data for SYNC-T Therapy SV-102 creates significant momentum for Syncromune and generates excitement within the oncology community. If the Phase 2a trial confirms these initial findings, SYNC-T could become a leading treatment option for mCRPC, significantly impacting patient outcomes and potentially reshaping the treatment paradigm for advanced prostate cancer. This development also underscores the potential of in situ personalized immunotherapy approaches for other solid tumors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
